ALEC Company Profile and Key Details

Q: Who are the executives of ALEC?

Mr. Calvin YuVice President of Fin.Dr. Tillman Ulf Gerngross Ph.D.Co-Founder & ChairmanMr. Peter Heutink Ph.D.Chief Scientific OfficerDr. Sara Kenkare-Mitra Ph.D.Pres and Head of R&DMs. Danielle Pasqualone J.D., Ph.D.Gen. CounselMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerErica JeffersonVice President of Communications & Public AffairsDr. Gary Romano M.D., Ph.D.Chief Medical OfficerMichelle CorralVice President of Communications & Investor RelationsDr. Marc Grasso M.D.AdvisorMs. Clare Hunt M.B.A.Chief People OfficerDr. Arnon Rosenthal Ph.D.Founder

NASDAQ : ALEC

Alector

$1.83

-0.1-5.18%

At Close 4:00 PM

60.69

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Alector, Inc. (ALEC) stock declined over -5.18%, trading at $1.83 on NASDAQ, down from the previous close of $1.93. The stock opened at $1.91, fluctuating between $1.81 and $1.94 in the recent session.

Stock Snapshot

1.93

Prev. Close

203.18M

Market Cap

1.805

Day Low

-1.54

P/E Ratio

-1.19

EPS (TTM)

-2.21

Cash Flow per Share

1.91

Open

111.03M

Number of Shares

1.94

Day High

83.56%

Free Float in %

1.59

Book Value

643.58K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	1.90	1.94	1.81	1.83	643.82K
Jul 07, 2026	1.97	1.97	1.86	1.93	416.16K
Jul 06, 2026	2.06	2.07	1.93	1.94	588.49K
Jul 02, 2026	2.02	2.15	2.00	2.06	393.98K
Jul 01, 2026	1.99	2.07	1.96	2.01	368.53K
Jun 30, 2026	2.10	2.13	1.98	2.01	609.36K
Jun 29, 2026	1.88	2.09	1.77	2.08	544.17K
Jun 26, 2026	1.84	1.96	1.84	1.86	3.85M
Jun 25, 2026	1.79	2.02	1.75	1.85	2.83M
Jun 24, 2026	1.78	1.87	1.78	1.79	510.35K
Jun 23, 2026	1.75	1.87	1.72	1.83	854K
Jun 22, 2026	1.76	1.92	1.72	1.78	1.59M
Jun 18, 2026	1.58	1.77	1.57	1.75	1.11M
Jun 17, 2026	1.55	1.60	1.53	1.56	496.02K
Jun 16, 2026	1.47	1.55	1.41	1.54	712.03K
Jun 15, 2026	1.56	1.60	1.46	1.48	629.57K
Jun 12, 2026	1.58	1.61	1.53	1.53	263.83K
Jun 11, 2026	1.52	1.74	1.49	1.57	428.2K
Jun 10, 2026	1.69	1.69	1.49	1.52	428.85K
Jun 09, 2026	1.64	1.68	1.59	1.63	439.47K

Contact Details

South San Francisco, CA 94080

United States

https://www.alector.com 415 231 5660

About Company

Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Alector, Inc. (NASDAQ:ALEC) closed at $1.83 USD, losing -$0.10 (-5.18%) from the previous close of $1.93. The stock is currently mid-range between its 52-week high and low $1.09 and $3.40. With a market capitalization of about $203.18 million, Alector, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 704.73 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Alector, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Arnon Rosenthal, the company employs approximately 103 people and listed since February 07, 2019. Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders.

Technical Performance

ALEC has shown mixed momentum, losing -0.54% over the past week and -39.8% over the past quarter, though year-to-date performance is up 17.31%. Short-term trend indicators are mixed aligned (SMA20 27.3%, SMA50 41.58%, SMA200 36.52%). The stock’s 14-day RSI is 82.29 (overbought), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.7% below its high and over 194.25% above its low. Average 10-day trading volume of 509.22 thousand shares is below the 3-month average of 703.01 thousand, indicating normal recent market interest.

Valuation Metrics

Alector, Inc. trades at a P/E ratio of -1.55, slightly below the S&P 500 average, with a price-to-sales ratio of 11.15 and a price-to-book ratio of 19.71 reflecting a rich premium to book value. The P/FCF stands at -1.19, also above market averages. Compared to sector medians, Alector, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Alector, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Alector, Inc. generated EPS of -$1.07 over the past year. Five-year average earnings growth is 6.31%. Wall Street analysts project EPS growth of 33.16% annually over the next five years. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.25. Next year's EPS is expected at -$19.15. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $3.50. The high target offers 227.87% upside. The low target suggests 91.26% downside. The mean target is $4.88. This offers 166.67% upside. Alector, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -27.03%. The prior quarter beat by -12.82%. Over the last six quarters, Apple has recorded several small beats. These include -96.72% in February 26, 2025.

Shareholding & Insider Activity

Alector, Inc. has 111.03 million shares outstanding. The public float is 93.80 million shares, elevated short interest at 5.01% of float. This equals 5.25 million shares. The short ratio is 7.0 days. Institutional investors hold 91.06% of the float. Insiders own 9.65%. MCGUIRE TERRANCE holds 10.85 million shares, Polaris Venture Management Co. VI, L.L.C. has 10.85 million shares and Rosenthal Arnon has 2.34 million shares. Over the past six months, insider transactions show net selling. They sold 129.85 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Alector generated $97.06M in revenue, or $1.16 per share. Gross margin was 90.88%, operating margin -156.33%, and net profit margin -134.34%. Returns are negative, with ROA at -20.97% and ROE at -97.19%.
On valuation metrics, Alector trades at a P/E of -1.55, P/S of 11.15 and P/B of 19.71. The current ratio is 5.25 and quick ratio is 5.25. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -17.49 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 3.33, supported by a cash flow-to-debt ratio of -5.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Alector posted revenue of $97.06M, down slightly from $133.62M in the prior quarter. Gross profit was $88.21M (margin 90.88%). Operating income was - $151.74M (margin -156.3%). Net income was- $130.39M (EPS - $1.56).
The company ended the quarter with $548.86M in cash and short-term investments, a total debt of $38.92M, and net debt of - $35.64M. Total assets were $621.83M, with equity of $134.16M. Financials further reflected weakness, with operating cash flow of - $184.16M, free cash flow of - $186.54M, and capital expenditures of - $2.38M.

Price Forecast & Outlook

Our AI price prediction model suggests that Alector, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.66%, with price expected at $2.08 by July 22, 2026, within a range of $1.92 to $2.24 3-Month Outlook: Projected fall of -9.29%, reaching $1.66 by October 06, 2026, with a range of $1.49 to $1.80. 1-Year Outlook: Projected gain of 40.98%, with price at $2.58 by July 08, 2027, within a range of $0.00 to $0.30.

Key Takeaways

Alector, Inc. (NASDAQ:ALEC) shares are up 17.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alector, Inc. trading at a premium to the broader market with a P/E of -1.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.65, suggesting 864.48% upside. Our AI forecast model points to short-term strength (13.66% over two weeks), a medium-term fall (-9.29% over three months), and a longer-term gain (40.98% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Alector, Inc. (ALEC) stock price?

Alector, Inc. (NASDAQ: ALEC) stock price is $1.83 in the last trading session. During the trading session, ALEC stock reached the peak price of $1.94 while $1.81 was the lowest point it dropped to. The percentage change in ALEC stock occurred in the recent session was -5.18% while the dollar amount for the price change in ALEC stock was - $0.10.

ALEC's industry and sector of operation?

The NASDAQ listed ALEC is part of Biotechnology industry that operates in the broader Healthcare sector. Alector, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALEC?

Mr. Calvin Yu
Vice President of Fin.
Dr. Tillman Ulf Gerngross Ph.D.
Co-Founder & Chairman
Mr. Peter Heutink Ph.D.
Chief Scientific Officer
Dr. Sara Kenkare-Mitra Ph.D.
Pres and Head of R&D
Ms. Danielle Pasqualone J.D., Ph.D.
Gen. Counsel
Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Erica Jefferson
Vice President of Communications & Public Affairs
Dr. Gary Romano M.D., Ph.D.
Chief Medical Officer
Michelle Corral
Vice President of Communications & Investor Relations
Dr. Marc Grasso M.D.
Advisor
Ms. Clare Hunt M.B.A.
Chief People Officer
Dr. Arnon Rosenthal Ph.D.
Founder

How ALEC did perform over past 52-week?

ALEC's closing price is 67.89% higher than its 52-week low of $1.09 where as its distance from 52-week high of $3.40 is -46.18%.

How many employees does ALEC have?

Number of ALEC employees currently stands at 175.

Link for ALEC official website?

Official Website of ALEC is: https://www.alector.com

How do I contact ALEC?

ALEC could be contacted at phone 415 231 5660 and can also be accessed through its website. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of ALEC are traded daily?

ALEC stock volume for the day was 643.58K shares. The average number of ALEC shares traded daily for last 3 months was 704.73K.

What is the market cap of ALEC currently?

The market value of ALEC currently stands at $203.18M with its latest stock price at $1.83 and 111.03M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	175
Beta	0.59
Sales or Revenue	$97.06M
5Y Sales Change%	1.863%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALEC Company Profile and Key Details

Alector

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook